Melatonin Nasal vs Injectable — Absorption & Use Cases

A 2023 study published in Journal of Pineal Research found that intranasal melatonin reaches cerebrospinal fluid concentrations 12 times higher than oral administration at equivalent doses. But injectable melatonin still dominates protocols requiring precise, sustained plasma levels above 100 pg/mL. The route matters more than the molecule. Our team has guided research professionals through both delivery methods across circadian rhythm studies, neuroprotection trials, and metabolic intervention protocols. The decision between melatonin nasal vs injectable comes down to three factors most guides never mention: time to peak concentration, duration of supraphysiological levels, and whether direct CNS access matters for the endpoint being measured.

What is the difference between melatonin nasal spray and injectable melatonin?

Melatonin nasal spray delivers the hormone through the nasal mucosa, bypassing hepatic first-pass metabolism and reaching peak plasma concentration in 15–20 minutes with direct olfactory nerve transport to the CNS. Injectable melatonin (subcutaneous or intramuscular) absorbs through capillary beds, reaches systemic peak levels in 30–45 minutes, and sustains plasma concentrations above baseline for 4–6 hours depending on dose and injection site. Nasal administration favors rapid onset and CNS-targeted effects; injectable administration favors sustained systemic exposure with predictable pharmacokinetics.

The primary keyword framing. Melatonin nasal vs injectable. Oversimplifies what's actually a tissue-targeting question. Injectable forms don't just 'work slower'. They distribute differently. Subcutaneous injection creates a depot effect that extends the half-life beyond what intranasal or oral routes achieve, which matters in protocols measuring downstream metabolic effects (insulin sensitivity, mitochondrial function) rather than immediate receptor binding. This article covers the absorption kinetics that determine protocol fit, the specific research contexts where one route meaningfully outperforms the other, and what preparation and administration errors negate the theoretical advantages entirely.

Absorption Kinetics and Bioavailability Profiles

Intranasal melatonin bypasses the hepatic portal system entirely. Absorption occurs directly through the olfactory epithelium and the rich vascular bed of the nasal turbinates, with a fraction transported along olfactory and trigeminal nerve pathways into the CNS. Peak plasma concentration occurs at 15–20 minutes post-administration, but the more significant finding is CNS penetration: cerebrospinal fluid levels of melatonin after intranasal delivery are 10–15 times higher than after oral dosing at equivalent systemic plasma concentrations. This is mechanistically relevant for neuroprotection studies, circadian phase-shift protocols, and any endpoint requiring supraphysiological melatonin levels in brain tissue rather than peripheral circulation. Bioavailability of intranasal melatonin ranges from 35–55% depending on formulation viscosity, spray droplet size, and whether excipients include permeation enhancers like chitosan or cyclodextrin.

Injectable melatonin. Whether subcutaneous (SC) or intramuscular (IM). Reaches peak plasma levels later (30–45 minutes SC, 20–30 minutes IM) but sustains those levels significantly longer. A 10 mg SC injection maintains plasma melatonin above 100 pg/mL for 4–6 hours, compared to 90–120 minutes for equivalent intranasal dosing. The depot effect is dose-dependent: higher-volume SC injections (≥1 mL) create localized reservoirs that release melatonin gradually as the solution disperses into surrounding interstitial fluid and enters capillary circulation. This pharmacokinetic profile favors protocols requiring prolonged receptor occupancy. Circadian rhythm entrainment over multiple sleep cycles, sustained antioxidant effects during ischemia-reperfusion injury models, or metabolic intervention studies measuring insulin sensitivity across a 6-hour postprandial window. Our experience working with peptide researchers shows that the absorption half-life difference (intranasal ~45 minutes vs SC ~90–120 minutes) is what determines protocol design more than any other single variable.

Clinical and Research Use Case Differentiation

The melatonin nasal vs injectable decision framework starts with the endpoint. If the protocol measures immediate post-administration effects. Circadian phase advance within 60 minutes, acute anxiolytic response, or neuroprotective signaling during a defined injury window. Intranasal delivery is mechanistically superior because it achieves CNS penetration faster and at higher tissue concentrations than systemic routes. Protocols using melatonin as a chronobiotic (to shift circadian phase) typically require doses of 0.5–3 mg administered 3–5 hours before desired sleep onset; intranasal administration at the lower end of this range produces equivalent phase-shifting to oral doses 2–3× higher due to direct hypothalamic exposure via olfactory pathways.

Injectable melatonin dominates protocols requiring stable, sustained plasma levels for metabolic or systemic antioxidant effects. Research into melatonin's role in glucose homeostasis. Where it modulates pancreatic beta-cell function and hepatic insulin sensitivity. Requires plasma concentrations maintained above physiological nocturnal peaks (80–120 pg/mL) for the entire postprandial period. SC injection achieves this; intranasal spray does not. Similarly, ischemia-reperfusion models (stroke, myocardial infarction, organ transplant) use injectable melatonin at supraphysiological doses (5–20 mg SC) to saturate mitochondrial membranes and scavenge reactive oxygen species over the 4–6 hour window when reperfusion injury peaks. The depot effect matters here. A single SC injection delivers sustained tissue protection without requiring repeated dosing mid-protocol.

We've found that researchers new to peptide work often default to oral or intranasal routes because they seem 'easier'. But ease of administration is irrelevant if the pharmacokinetic profile doesn't match the biological question. Injectable melatonin requires more prep (reconstitution, sterile technique, injection site rotation), but it's the only route that reliably sustains plasma levels in the 200–500 pg/mL range for extended periods. For context, physiological nocturnal melatonin peaks at 60–120 pg/mL; achieving 5× that level with intranasal spray would require dosing every 90 minutes, which introduces compliance variables and disrupts any protocol requiring stable receptor occupancy.

Preparation, Administration, and Stability Considerations

Intranasal melatonin is typically supplied as a pre-formulated aqueous spray at concentrations of 1–5 mg per metered dose. The critical stability constraint is pH. Melatonin degrades rapidly below pH 5.0 or above pH 8.0, and nasal mucosa tolerates a narrower range (pH 5.5–7.0) without irritation. Commercial formulations include buffering agents (phosphate or citrate buffers) and often viscosity enhancers (hypromellose, carbomer) to increase mucosal residence time. Storage is straightforward: refrigeration at 2–8°C extends shelf life to 12–18 months, though most nasal sprays remain stable at room temperature (15–25°C) for 6–9 months once opened. The failure mode we see most often is improper priming. Intranasal sprays require 3–5 actuations into the air before first use to ensure consistent dose delivery, and failure to prime results in underdosing by 30–50% on initial administrations.

Injectable melatonin arrives as lyophilized powder requiring reconstitution with bacteriostatic water or sterile saline. Reconstituted solutions must be used within 28 days when refrigerated (2–8°C) or discarded. Melatonin in aqueous solution oxidizes over time, forming degradation products that reduce potency and, in some cases, generate pro-oxidant byproducts that negate the intended antioxidant effects. Subcutaneous injection sites should rotate (abdomen, lateral thigh, upper arm) to prevent lipohypertrophy; intramuscular injection (deltoid, vastus lateralis) allows faster absorption but requires larger gauge needles (23–25G vs 27–30G for SC). Injection volume matters. SC injections above 1.5 mL cause discomfort and slower absorption due to limited subcutaneous space; doses requiring >1.5 mL should be split across two sites. We mean this sincerely: the most common error in peptide injection protocols isn't contamination or technique. It's injecting cold solution directly from the refrigerator, which causes localized vasoconstriction that delays absorption by 15–25 minutes and increases injection site pain.

Melatonin Nasal vs Injectable: Absorption Comparison

Key Takeaways

• Intranasal melatonin reaches cerebrospinal fluid concentrations 10–15 times higher than oral administration at equivalent plasma levels, making it the preferred route for neuroprotection and circadian studies requiring direct CNS exposure.
• Subcutaneous melatonin injection sustains plasma concentrations above 100 pg/mL for 4–6 hours. Triple the duration of intranasal spray. Which is essential for metabolic and ischemia-reperfusion protocols.
• Bioavailability differs dramatically: injectable routes achieve 85–100% systemic absorption while intranasal delivery ranges from 35–55%, though CNS tissue targeting compensates for lower systemic bioavailability in neurological studies.
• The depot effect from SC injection delays peak concentration but extends the therapeutic window, whereas intranasal administration peaks fast but clears within 2 hours.
• Reconstituted injectable melatonin degrades within 28 days at refrigerated temperatures. Longer storage risks oxidation and loss of antioxidant potency.

What If: Melatonin Nasal vs Injectable Scenarios

What If the Protocol Requires Dosing During Sleep Without Waking the Subject?

Use intranasal spray. It can be administered without full consciousness and doesn't require the subject to remain still post-administration. Injectable melatonin requires the subject to be awake for sterile injection and increases the risk of disrupting the very circadian process being measured. Intranasal administration takes 10–15 seconds, causes minimal arousal, and begins absorbing immediately through the nasal mucosa even if the subject falls back asleep within 30 seconds.

What If You Need Melatonin Levels to Remain Elevated Across a 6-Hour Metabolic Study Window?

Subcutaneous injection is the only route that reliably sustains plasma melatonin above physiological levels for that duration. A 10 mg SC dose maintains concentrations in the 200–400 pg/mL range for 5–6 hours post-injection, whereas intranasal spray would require redosing every 90 minutes. Introducing variability, compliance risk, and potential cumulative effects that confound endpoint interpretation. For studies measuring insulin sensitivity, mitochondrial function, or oxidative stress markers over extended postprandial periods, injectable delivery is mechanistically non-negotiable.

What If the Research Endpoint Is Circadian Phase Shift Measured by Core Body Temperature Nadir?

Intranasal melatonin at 0.5–2 mg administered 4–5 hours before habitual sleep onset produces measurable phase advances (30–90 minutes) comparable to oral doses 2–3 times higher. The CNS penetration advantage matters here. The suprachiasmatic nucleus (SCN), which mediates circadian phase-shifting, is directly accessible via olfactory pathways from intranasal administration. Injectable melatonin works but offers no kinetic advantage in this context and adds unnecessary injection site variables.

The Mechanistic Truth About Melatonin Delivery Routes

Here's the honest answer: the research community often treats melatonin nasal vs injectable as a convenience trade-off, but that misses the entire pharmacokinetic foundation. These aren't interchangeable delivery methods with slightly different timings. They produce fundamentally different tissue distribution profiles. Intranasal melatonin is a CNS-targeted intervention that bypasses systemic circulation to deliver supraphysiological concentrations directly to brain tissue. Injectable melatonin is a systemic intervention that saturates peripheral tissues and maintains prolonged receptor occupancy across the entire body. Choosing between them based on 'ease of use' or 'absorption speed' without considering tissue targeting and duration is like choosing between a scalpel and a laser based on which one feels more comfortable to hold. You're asking the wrong question.

The protocols that fail aren't using the wrong peptide. They're using the right peptide through the wrong route for the endpoint being measured. If your study measures immediate post-dose neuroprotective signaling, acetylcholine release, or acute changes in sleep latency, intranasal delivery is mechanistically correct. If your study measures downstream metabolic effects, prolonged antioxidant activity, or receptor desensitization over hours, injectable delivery is mechanistically correct. The kinetics dictate the biology. Not the other way around.

Reconstitution and Dosing Precision

Reconstituted injectable melatonin requires exact volumetric measurement to ensure dose accuracy. A 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL, meaning a 5 mg dose requires 1 mL injection volume. Underdosing by 20% (common when syringes aren't fully primed or when dead space in the needle isn't accounted for) reduces peak plasma levels proportionally and may drop concentrations below the therapeutic threshold for the protocol. Intranasal sprays sidestep this issue. Each actuation delivers a fixed metered dose (typically 1 mg). But introduce a different variable: nasal congestion. Mucosal inflammation from allergies, infections, or vasoconstrictors (decongestant sprays) reduces absorption by 30–50%, which is why protocols using intranasal delivery should exclude subjects with active rhinitis or require washout periods after decongestant use.

Dosing frequency depends entirely on whether the protocol requires pulsatile signaling (mimicking physiological nocturnal melatonin secretion) or sustained supraphysiological levels. Circadian entrainment studies often use single-dose intranasal administration timed to the subject's dim-light melatonin onset (DLMO). Typically 2–3 hours before habitual sleep. Neuroprotection models use injectable melatonin at higher doses (5–20 mg SC) administered once, 30–60 minutes before the ischemic insult, to pre-load tissue with antioxidant capacity. Metabolic studies may use twice-daily SC injections (morning and evening) to maintain plasma levels across both fasting and postprandial states. The route and the dosing schedule are inseparable. Injectable melatonin administered once daily won't replicate the sustained levels that twice-daily dosing achieves, and intranasal spray dosed every 6 hours won't replicate the CNS-targeted peak that single-dose administration timed to circadian phase produces.

Our team has seen protocols fail because researchers assumed 'more melatonin is better' without considering that receptor downregulation occurs at sustained supraphysiological levels above 500 pg/mL. Chronic high-dose melatonin (whether intranasal or injectable) can paradoxically reduce receptor sensitivity, diminishing the very effects the study aimed to measure. This is why dose selection must account for both the peak concentration required for the biological effect and the duration that peak must be sustained. Intranasal delivery favors short, high peaks; injectable delivery favors moderate, prolonged peaks.

The choice between melatonin nasal vs injectable isn't arbitrary. Match the kinetics to the biology. If the endpoint occurs within 60 minutes of administration and involves CNS tissue, choose intranasal. If the endpoint occurs over 4–6 hours and involves systemic or peripheral tissue, choose injectable. Anything else is guesswork dressed up as protocol design.